Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/20/2012EP2465498A1 Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
06/20/2012EP2465497A1 Pharmaceutical suspension composition
06/20/2012EP2465495A1 Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles
06/20/2012EP2465494A2 Injectable composition containing hydroxychloroquine for local administration for treating cancer
06/20/2012EP2465492A1 Compositions comprising sphingosine I phosphate (sip) receptor modulators
06/20/2012EP2465357A2 Stabilized ß cryptoxanthin-containing water and the use thereof
06/20/2012EP2464731A2 Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
06/20/2012EP2464730A1 miRNA COMPOUNDS FOR TREATMENT OF PROSTATE CARCINOMA
06/20/2012EP2464724A2 Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products
06/20/2012EP2464668A2 Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof
06/20/2012EP2464667A2 N-acylated octasaccharides activating fgfs receptors, their synthesis and their therapeutical application
06/20/2012EP2464664A1 Antibodies against human respiratory syncytial virus (rsv) and methods of use
06/20/2012EP2464653A2 Method for making 3 -hydroxy, 3 - methyl-5 -pregnan-20-one (ganaxolone)
06/20/2012EP2464651A1 New macrolides and their use
06/20/2012EP2464650A2 Processes for preparing pemetrexed
06/20/2012EP2464649A1 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
06/20/2012EP2464647A1 Azaindazoles as btk kinase modulators and use thereof
06/20/2012EP2464645A1 Fused heterocyclic compounds as ion channel modulators
06/20/2012EP2464644A1 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
06/20/2012EP2464642A1 Method of promoting apoptosis and inhibiting metastasis
06/20/2012EP2464641A1 Pyrimidine compounds as tuberculosis inhibitors
06/20/2012EP2464640A1 Inhibitors of jnk
06/20/2012EP2464639A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors
06/20/2012EP2464638A1 Lenalidomide salts
06/20/2012EP2464632A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors
06/20/2012EP2464629A1 Selective sphingosine-1-phosphate receptor antagonists
06/20/2012EP2464626A1 Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
06/20/2012EP2464423A1 Methods and compositions for treating leukemia
06/20/2012EP2464388A1 Particulate hyaluronic acid formulations for cellular delivery of bioactive agents
06/20/2012EP2464387A2 Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method for use
06/20/2012EP2464382A1 Combination therapy of an afucosylated cd20 antibody with bendamustine
06/20/2012EP2464380A1 Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
06/20/2012EP2464359A2 N-sulfated oligosaccharides activating fgfs receptors, their synthesis and their therapeutical application
06/20/2012EP2464358A2 Improved pharmacokinetics of s-adenosylmethionine formulations
06/20/2012EP2464357A2 Vitamin d3 and analogs thereof for treating alopecia
06/20/2012EP2464356A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy
06/20/2012EP2464355A1 Substituted triazolophthalazine derivatives
06/20/2012EP2464354A1 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
06/20/2012EP2464353A1 Triazine derivates for use in the treatment of malaria
06/20/2012EP2464352A1 Use of e5501 for stimulating platelet production
06/20/2012EP2464351A1 Isothiozoles for treating conditions of the eye
06/20/2012EP2464350A2 Compositions and methods for enhancing cognitive and related functions in animals
06/20/2012EP2464349A2 Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
06/20/2012EP2464348A1 Combination of proantocyanidins such as pycnogenol or grape seeds and centella asiatica for the treatment of cardiovascular disorders such as atherosclerosis
06/20/2012EP2464347A1 Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
06/20/2012EP2464346A1 Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
06/20/2012EP2464345A2 Treatment of viral infections
06/20/2012EP2464343A1 Ophthalmic drug delivery system containing phospholipid and cholesterol
06/20/2012EP2464342A2 Novel pharmaceutical formulations against drug misuse
06/20/2012EP2464340A2 Pharmaceutical compositions with tetrabenazine
06/20/2012EP2464339A2 Steroid solvates
06/20/2012EP2464338A1 Dry powder inhaler formulations
06/20/2012EP2464337A1 Pharmaceutical composition and administrations thereof
06/20/2012EP2464336A2 Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
06/20/2012EP2464335A1 Pharmaceutical composition including a dha ester to be parenterally administered
06/20/2012EP2464334A1 Compositions and methods for treating fungal infection of the nail
06/20/2012EP2464333A2 Floating microgranules
06/20/2012EP2464332A1 Storage-stable formulation of paracetamol in aqueous solution
06/20/2012EP2464331A1 Stabilised particles comprising 5-methyl-(6s)-tetrahydrofolate
06/20/2012EP2464247A2 Nutritional supplements
06/20/2012EP2464236A1 Anti-infective antimicrobial-containing biomaterials
06/20/2012EP2464234A1 Methods for iontophoretically treating nausea and migraine
06/20/2012EP2464232A1 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
06/20/2012EP2464231A1 Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
06/20/2012EP2464230A1 Intravenous formulations of neurokinin-1 antagonists
06/20/2012EP2464229A1 Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
06/20/2012EP2464228A1 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
06/20/2012EP2464227A1 Compounds and methods of use thereof
06/20/2012EP2464225A1 Process for the synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5'7'-tetraiodo-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one (rose bengal) and related xanthenes
06/20/2012EP2464218A2 Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
06/20/2012EP2364731A9 Methods of administering anti-TNFalpha antibodies
06/20/2012EP2359855A9 Methods of administering anti-TNFalpha antibodies
06/20/2012EP2303268B1 Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use
06/20/2012EP2303233B1 Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
06/20/2012EP2300473B1 Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof
06/20/2012EP2297177B1 C-ring-substituted pregn-4-ene-21,17-carbolactone, and pharmaceutical preparations comprising the latter
06/20/2012EP2271332B1 Use of compounds in the treatment of tauopathy
06/20/2012EP2252581B1 Kappa selective opioid receptor antagonist
06/20/2012EP2227460B1 Therapeutic oxy-phenyl-aryl compounds and their use
06/20/2012EP2222312B1 Aqueous iron dextran preparation having one or more para-hydroxybenzoate compounds and/or salts thereof
06/20/2012EP2203442B1 Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
06/20/2012EP2172195B1 Cholesterol-control agent
06/20/2012EP2152707B1 [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
06/20/2012EP2146735B1 Compositions comprising sparc polypeptides
06/20/2012EP2144881B1 Isoquinolinone derivatives, processes for their preparation and their use in the treatment of chronic obstructive pulmonary disease ( copd ) and asthma
06/20/2012EP2121614B1 Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors
06/20/2012EP2120584B1 Silylated piperidine derivatives
06/20/2012EP2102169B1 Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
06/20/2012EP2021321B1 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
06/20/2012EP2012773B1 Drugs and uses
06/20/2012EP1963276B1 N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
06/20/2012EP1912996B1 Macrocyclic inhibitors of hepatitis c virus
06/20/2012EP1910378B1 Hepatitis c inhibitor peptide analogs
06/20/2012EP1904512B1 Purine derivatives as agonists of the adenosine a2a receptor
06/20/2012EP1901712B1 Therapeutic sclerosing foam made preferably from xenon
06/20/2012EP1890678B1 Therapeutic sclerosing foam containing xenon
06/20/2012EP1874733B1 Substituted cyclic urea derivatives and the use thereof as vanilloid receptor 1 modulators
06/20/2012EP1858895B1 Piperazine-piperidines with cxcr3 antagonist activity
06/20/2012EP1852130B1 Medicine for external application containing anti-inflammatory agent and soy lecithin
06/20/2012EP1832288B1 Stable granular pharmaceutical composition of solifenacin or its salt
1 ... 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 ... 7860